Catalyst Pharmaceuticals (CPRX) Operating Leases (2019 - 2026)

Catalyst Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Operating Leases fell 16.64% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 16.64% YoY) and the FY2025 annual result came in at $2.4 million, down 15.65% from the prior year.
• Operating Leases was $2.2 million for Q1 2026 at Catalyst Pharmaceuticals, down from $2.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $4.1 million in Q2 2022 and bottomed at $2.2 million in Q1 2026.
• A 5-year average of $3.2 million and a median of $3.2 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases changed 0.0% — and 2025, when it retreated 22.69%.
• Catalyst Pharmaceuticals' Operating Leases stood at $3.6 million in 2022, then slipped by 10.37% to $3.2 million in 2023, then declined by 12.61% to $2.8 million in 2024, then fell by 15.65% to $2.4 million in 2025, then declined by 4.89% to $2.2 million in 2026.
• Business Quant data shows CPRX's Operating Leases at $2.2 million in Q1 2026, $2.4 million in Q4 2025, and $2.5 million in Q3 2025.